drugset / Trial / NCT04483960

Summary

An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients with SARS-CoV-2 Infection (COVID-19).

Timeline

Start
2020-07-28
Primary completion
2025-07-25
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 100 iu/kg
Subject Dalteparin sodium Other / unclassified 200 iu/kg
Subject Enoxaparin sodium Other / unclassified 1 mg/kg
Subject Enoxaparin sodium Other / unclassified 1.5 mg/kg
Subject Hyperimmune globulin Protein / enzyme biologic 30 ml
Subject Nafamostat Small molecule 0.2 mg/kg Intravenous
Subject Nirmatrelvir Small molecule 150 mg Oral
Subject Nirmatrelvir Small molecule 300 mg Oral
Subject Remdesivir Small molecule 100 mg Intravenous
Subject Ritonavir Other / unclassified 100 mg Oral
Subject Tinzaparin Other / unclassified 175 iu/kg

Indications